Interestingly, we observed significantly increased sleep bout lengths during the dark phase (1800–2100 and 0000–0300 hours, respectively) in AD-tau–injected APPPS1:E4 but not APPPS1:E3 mice after 7 weeks of SD treatment compared with the first week of SD (Figure 9, C and D). Here, MAPT is linked to Alzheimer disease.